Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA4 | P22748 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | ENO1 | P06733 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22368126 | 1.00 | MEN1 (0.41) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL28672982 | 0.98 | MEN1 (0.38) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL20115945 | 0.87 | MEN1 (0.45) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL23128359 | 0.87 | MEN1 (0.38) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL19172671 | 0.86 | CA2 (0.49) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL23822616 | 0.85 | CA2 (0.42) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL20904578 | 0.84 | CA2 (0.44) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL20017289 | 0.84 | MEN1 (0.41) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL24040332 | 0.84 | MEN1 (0.41) | MEN1KMT2ACA2CA12CA1 | |
| SCHEMBL21415394 | 0.84 | CA2 (0.44) | MEN1KMT2ACA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320815-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9725405-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160159732-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9227943-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150126706-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8993295-B2 | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting | THE GENERAL HOSPITAL CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2222341-B1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIV GEORGIA (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8940859-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20120322974-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120172575-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8133515-B2 | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100055761-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING | THE GENERAL HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20080306008-A1 | Peptides for Use in the Treatment of Obesity | NOVA NORDISK A/S (DK) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306008-A1 | Peptides for Use in the Treatment of Obesity | MC4R, GIPR, MC3R | MEN1 553/4885KMT2A 3130/4885CA2 2667/4885 |
| US-20100297250-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | MEN1 1074/4885KMT2A 3873/4885CA2 969/4885 |
| US-20120040011-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | MEN1 1074/4885KMT2A 3873/4885CA2 969/4885 |
| US-20170320815-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | MEN1 1074/4885KMT2A 3873/4885CA2 969/4885 |
| US-20120322974-A9 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | MEN1 1074/4885KMT2A 3873/4885CA2 969/4885 |
| US-20150126706-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | MEN1 1074/4885KMT2A 3873/4885CA2 969/4885 |
| US-20120172575-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | MEN1 1074/4885KMT2A 3873/4885CA2 969/4885 |
| US-20160159732-A1 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS | ALG1, ST3GAL3, B3GNT2 | MEN1 1074/4885KMT2A 3873/4885CA2 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.